Summary
Zoetis Inc. announced on January 14, 2016, an agreement to divest its 55% ownership stake in a manufacturing site located in Hsinchu, Taiwan, to Yung Shin Pharmaceutical Industrial Co., Ltd. This divestment includes the transfer of manufacturing and commercial employees associated with the site, as well as a portfolio of products. These products primarily consist of medicated feed additives, anti-infectives, and nutritional premixes for livestock, with sales mainly in Taiwan and other international markets. The transaction, valued at approximately $13 million in cash for Zoetis, is considered not material to the company's overall financial standing. This move is a strategic component of Zoetis's ongoing operational efficiency program, initiated in May 2015, aimed at streamlining operations, optimizing resource allocation, and fostering long-term profitable growth. The divestiture aligns with the program's objectives to reduce complexity and enhance the efficiency and reliability of Zoetis's supply network.
Key Highlights
- 1Zoetis to divest 55% ownership of Taiwan manufacturing site and associated product portfolio.
- 2Purchaser is Yung Shin Pharmaceutical Industrial Co., Ltd., based in Taiwan.
- 3Transaction includes transfer of all manufacturing and commercial employees at the legal entity to Yung Shin.
- 4Divested products include medicated feed additives, anti-infectives, and nutritional premixes for livestock.
- 5Zoetis expects to receive approximately $13 million in cash from the sale.
- 6The transaction is not considered material to Zoetis Inc.
- 7Divestment is part of Zoetis's broader operational efficiency program to reduce complexity and optimize resources.